Cerebrospinal Fluid Pharmacokinetics of Tigecycline in Lumbar and Ventricular Compartments After Lumbar Intrathecal Administration: A Three-Patient Case Series
Abstract
Background: Lumbar intrathecal administration of tigecycline has been increasingly used as a salvage treatment for multidrug-resistant (MDR) intracranial infections. However, whether lumbar administration can generate adequate tigecycline exposure in ventricular cerebrospinal fluid (CSF), remains insufficiently characterized.
Case presentation: We retrospectively analyzed three patients with intracranial infections who received 5mg tigecycline through a lumbar drainage catheter and had concurrent lumbar and ventricular CSF access. The underlying conditions were postoperative primary meningioma, brain abscess, and traumatic cerebral contusions, respectively. The identified pathogens included Acinetobacter johnsonii (tigecycline MIC, 0.5 mg/L), Aspergillus fumigatus, and Klebsiella pneumoniae (tigecycline MIC, 2.0 mg/L). Paired lumbar and ventricular CSF samples were collected at scheduled time points after dosing, and tigecycline concentrations were quantified by liquid chromatography-tandem mass spectrometry (LC‑MS/MS). Following a 5 mg lumbar intrathecal dose, the lumbar CSF peak concentration (Cmax) was reached within 1 hour across all patients (933.89, 269.07, and 256.71 mg/L). In contrast, the ventricular Cmax values were substantially lower (0.67, 7.05, and 2.64 mg/L), with ventricular time to peak concentration (Tmax) delayed to 4-6 hours. The ventricular‑to‑lumbar area‑under‑the‑curve ratio (V/L AUC1-24h ratio), ranged from 0.33% to 7.13%, indicating markedly…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.